1. Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges
- Author
-
Siqi Gong, Samir K. Lakhashe, Dinesh Hariraju, Hanna Scinto, Antonio Lanzavecchia, Elisabetta Cameroni, Davide Corti, Sarah J. Ratcliffe, Kenneth A. Rogers, Peng Xiao, Jane Fontenot, François Villinger, and Ruth M. Ruprecht
- Subjects
0301 basic medicine ,medicine.drug_class ,IgG ,passive mucosal and systemic immunization ,Immunology ,Simian Acquired Immunodeficiency Syndrome ,Pilot Projects ,Viremia ,HIV Antibodies ,Monoclonal antibody ,Virus ,03 medical and health sciences ,0302 clinical medicine ,dimeric IgA ,rhesus macaque model ,immune exclusion ,Animals ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,Immunity, Mucosal ,Original Research ,biology ,business.industry ,Anti hiv ,Immunization, Passive ,Antibodies, Monoclonal ,RC581-607 ,medicine.disease ,Antibodies, Neutralizing ,Macaca mulatta ,030104 developmental biology ,Immunization ,SHIV ,Monoclonal ,HIV-1 ,biology.protein ,Simian Immunodeficiency Virus ,Antibody ,Immunologic diseases. Allergy ,business - Abstract
Understanding the interplay between systemic and mucosal anti-HIV antibodies can provide important insights to develop new prevention strategies. We used passive immunization via systemic and/or mucosal routes to establish cause-and-effect between well-characterized monoclonal antibodies and protection against intrarectal (i.r.) SHIV challenge. In a pilot study, for which we re-used animals previously exposed to SHIV but completely protected from viremia by different classes of anti-HIV neutralizing monoclonal antibodies (mAbs), we made a surprise finding: low-dose intravenous (i.v.) HGN194-IgG1, a human neutralizing mAb against the conserved V3-loop crown, was ineffective when given alone but protected 100% of animals when combined with i.r. applied HGN194-dIgA2 that by itself had only protected 17% of the animals. Here we sought to confirm the unexpected synergy between systemically administered IgG1 and mucosally applied dIgA HGN194 forms using six groups of naïve macaques (n=6/group). Animals received i.v. HGN194-IgG1 alone or combined with i.r.-administered dIgA forms; controls remained untreated. HGN194-IgG1 i.v. doses were given 24 hours before – and all i.r. dIgA doses 30 min before – i.r. exposure to a single high-dose of SHIV-1157ipEL-p. All controls became viremic. Among passively immunized animals, the combination of IgG1+dIgA2 again protected 100% of the animals. In contrast, single-agent i.v. IgG1 protected only one of six animals (17%) – consistent with our pilot data. IgG1 combined with dIgA1 or dIgA1+dIgA2 protected 83% (5/6) of the animals. The dIgA1+dIgA2 combination without the systemically administered dose of IgG1 protected 67% (4/6) of the macaques. We conclude that combining suboptimal antibody defenses at systemic and mucosal levels can yield synergy and completely prevent virus acquisition.
- Published
- 2021